Generex Announces Sales Agreement with Elias Shaker & Company

WORCESTER, Mass., Sept. 20 /PRNewswire/ -- Generex Biotechnology Corporation (Nasdaq: GNBT), (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has entered into a sales agreement with Elias Shaker & Company (www.eliasshaker.com), a leading national full-service consumer product brokerage firm, to represent Generex's novel consumer products to national and regional retail and wholesale accounts in the USA.

Founded in 1924 by Elias Shaker, the company has established itself as a respected, quality-conscious, service-driven organization committed to producing measurable results.  Elias Shaker & Company has established relationships with all class of trades from national drug chains and wholesalers to mass merchandisers/club stores, grocery chains, food wholesalers, convenience stores and distributors and specialty stores, representing a total of more than 200,000 retail points of purchase throughout the USA.

"We are very excited to partner with an experienced and results-driven sales firm such as Elias Shaker to represent our proprietary consumer products in the USA," said Rose Perri, the Company's Chief Operating Officer.  "We welcome the opportunity to have our products showcased and represented by a company with an extensive history in retail."

"After reviewing Generex's consumer products, its current distribution and discussing it with our sales team internally we are very confident in taking their product-line to the next level by focusing on building new distribution, supporting established accounts and taking advantage of unique promotional opportunities that may arise which will ultimately grow brand awareness and sales," said Bruce Funk, Elias Shaker & Company's President.

Elias Shaker & Company will market and sell the following Generex consumer products:  Glucose RapidSpray™ (www.GlucoseRapidSpray.com),  Crave-NX™ Diet Aid Spray (www.Crave-NX.com), BaBOOM!™ Energy Spray (www.BaboomEnergySpray.com), and Glucose RapidSpray™ for Pets (www.GlucoseRapidSprayPets.com).

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's flagship product, buccal insulin (Generex Oral-lyn™), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

About Elias Shaker & Company

Founded in 1924 by Elias Shaker, Elias Shaker & Company is one of the leading consumer products broker, sales and marketing Service companies in the USA.  The Company has established itself as a respected, quality-conscious, service-driven organization committed to producing measurable results.  As a full-service consumer product brokerage firm, the Company expertly provides a variety of professional sales and marketing services to the retail and wholesale trades.  Over 85 years, the Company has earned a reputation for producing maximum sales results and providing outstanding services to both our manufacturing principals and retail accounts and has successfully generated millions of additional sales dollars for representative manufacturing companies.  The Company markets and sell to thousands of major retail and wholesale outlets and establishments, represented many leading consumer product manufacturers and their products and received numerous honors for exceptional sales performance and marketing success.  For more information, visit the Elias Shaker & Company at www.eliasshaker.com.

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED